Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
Zacks에서 열기
Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say

Ionis Pharmaceuticals (IONS) reported $243 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 54.8%. EPS of -$0.40 for the same period compares to -$0.61 a year ago.

The reported revenue represents a surprise of +35.81% over the Zacks Consensus Estimate of $178.93 million. With the consensus EPS estimate being -$1.00, the EPS surprise was +60%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Ionis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Total commercial revenue: $136 million versus the eight-analyst average estimate of $140.09 million. The reported number represents a year-over-year change of +17.2%. Revenue- Product sales, net: $48 million versus the eight-analyst average estimate of $56.46 million. The reported number represents a year-over-year change of +50%. Revenue- Total research and development revenue: $107 million versus the eight-analyst average estimate of $38.84 million. The reported number represents a year-over-year change of +161%. Revenue- Royalty revenue- SPINRAZA royalties: $69 million versus the seven-analyst average estimate of $55.98 million. The reported number represents a year-over-year change of +23.2%. Revenue- Commercial revenue- Other commercial revenue: $7 million versus the seven-analyst average estimate of $5.16 million. The reported number represents a year-over-year change of -12.5%. Revenue- Royalty revenue- WAINUA royalties: $7 million compared to the $17.67 million average estimate based on seven analysts. Revenue- Royalty revenue: $81 million compared to the $78.28 million average estimate based on seven analysts. Revenue- Product sales net- DAWNZERA sales: $37 million versus $33.15 million estimated by seven analysts on average. Revenue- Product sales net- TRYNGOLZA sales: $9 million compared to the $23.09 million average estimate based on seven analysts. Revenue- Royalty revenue- Other royalties: $5 million compared to the $3.96 million average estimate based on six analysts. The reported number represents a change of -28.6% year over year. Revenue- Research and development revenue- WAINUA joint development revenue: $4 million compared to the $13.7 million average estimate based on five analysts. Revenue- Research and development revenue- Collaborative agreement revenue: $103 million compared to the $19 million average estimate based on five analysts. The reported number represents a change of +232.3% year over year.

View all Key Company Metrics for Ionis Pharmaceuticals here>>>

Shares of Ionis Pharmaceuticals have returned -12.9% over the past month versus the Zacks S&P 500 composite's -5.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research